RxDoctor Payments Data

Micheal Kaiser, APRN

Family · Sierra Vista, AZNPI 1053037812

Payments from drug & device makers

$1,670in general payments, 2019–2025

Across 95 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$348
  • Amgen$328
  • GSK$251
  • Novo Nordisk$144
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$109
  • AstraZeneca$105
  • plus $385 from 15 others

What the payments were for

  • Food & beverage$1,670100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,670 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$128,626
Medicare patients
323
Services billed
2,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$75,119
EliquisApixaban91$68,958
OzempicSemaglutide42$63,775
JardianceEmpagliflozin50$48,022
FarxigaDapagliflozin Propanediol41$32,769
Repatha SureclickEvolocumab15$24,239
MounjaroTirzepatide17$22,891
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$15,293
Advair HfaFluticasone Propion/Salmeterol12$4,900
BrilintaTicagrelor11$4,242
Aripiprazole26$3,618
Celecoxib83$3,150
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,062
Levothyroxine Sodium289$2,891
Gabapentin134$2,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$251$90,41190 claims
PfizerEliquis$33$68,95891 claims
Novo NordiskOzempic$144$63,77542 claims
AstraZenecaFarxiga, Brilinta$105$37,01152 claims
Lilly USA, LLCMounjaro$48$22,89117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Sierra Vista

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →